AbbVie To Acquire Aliada Therapeutics for $1.4 Bn
AbbVie has agreed to acquire Aliada Therapeutics, a bio/pharmaceutical company focused on central nervous system diseases, for $1.4 billion.
Aliada’s lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody for treating Alzheimer’s disease, currently in Phase I development.
Under the agreement, AbbVie will acquire all outstanding Aliada equity for $1.4 billion in cash, subject to certain customary adjustments. The transaction is expected to close in the fourth quarter of 2024, subject to regulatory approvals and other customary closing conditions.
Source: AbbVie